エクラー軟膏0.3%、エクラークリーム0.3%、エクラーローション0.3%_IF
|
|
- せせら かみこ
- 7 years ago
- Views:
Transcription
1 IF g 3mg(0.3%) Deprodone Propionate ( ) ( ) F A X IF
2 IF 1. MR 63 2 IF 10 3 IF 2. IF IF IF 3. IF A4 9 IF IF IF 11 1 IF IF 4. IF IF MR IF IF MR Drug Safety Update IF
3
4
5 (1) (2) (3) 84.3%(721 /855 ) 96.3%(823 /855 ) 81.4%(664 / %(765 /816 ) 78.5%(520 / %(613 /662 ) (4) 1.0%(9 /859 ) 2.1%(17 /824 ) 1.6%(12 /728 ) - 1 -
6 0.3% 0.3% 0.3% ECLAR OINTMENT 0.3%, ECLAR CREAM 0.3%, ECLAR LOTION 0.3% JAN Deprodone Propionate INN C24H32O (+)-11,17-dihydroxy-1,4-pregnadiene-3,20-dione 17-propionate - 2 -
7 CAS
8 Britton-Robinson (ph210) ( / ) D α g 20mL100mm - 4 -
9 (1) 2mg 2mL 365nm 10mL (2) (1100)1mL 1mL 2 (3) 0.05g 2mL 5 272mL 1 (4) ( ) - 5 -
10 - 6 -
11 1g 3mg0.3 ph (200 ) 3 50m 0.5% ph HP2100-O( ) HP2101C( ) HP2102L( ) 1g 3mg
12 1) - 8 -
13 1) 2) - 9 -
14 1) 0.7g( 2mg ) 10mL 10 30mL 10 1mL 1mL 2 2) 0.7g 10mL 10 30mL 10 1mL 0.02g 10mL 5L (60:15:10:3) 12cm ( 365nm) Rf (0.3) 1) 0.7g( 2mg ) 30mL 30mL 2 1mL 1mL 2 2) 0.7g 30mL 30mL 2 1mL 0.02g 10mL 5L (60:15:10:3) 12cm ( 365nm) Rf (0.3) 1) 0.7g( 2mg ) 20mL 2g 30mL 2 1mL 1mL
15 2) 0.7g 20mL 2g 30mL 2 1mL 0.02g 10mL 5L (60:15:10:3) 12cm ( 365nm) Rf (0.3) 1)3) 0.7g( 2mg ) 20mL 2g 30mL 3 100mL 10mL 10mL g 100mL 2mL 50mL 10mL 10mL 20L QT QS (mg) (mg)qt/qs1/25 n- (120000)
16 ( ) ( ) ( )
17 - 13 -
18 DNA RNA DNA mrna mrna mrna 7)8) 30mg (p<0.01) (p<0.01)
19
20 DP-O Control DP-O 34 5 BV-O DP-O DP-C Control DP-C 34 5 BV-C DP-C ( ) 2 50mg 11) (mg) (%) (mg/100gb.w.) Control DP-O DP-O **,## 31.9 (34.2 a ) **,# BV-O ** **,$$ ( S.E.) DP-O 7 Control DP-O BV-O DP-O BV-O DP-O
21 (mg) (%) (mg/100gb.w.) Control DP-C * DP-C **,## 40.9 (41.7 a ) ** BV-C ** **,$$ ( S.E.) DP-C 7 Control DP-C BV-C DP-C BV-C DP-C BV-O Control 3 (17 )7 (21 ) DP-O BV-O 3 (17 ) 7 (21 ) DP-O BV-O
22 ( ) mg
23 1) 14) 5 2g( 6mg)12 EIA (DP) 12 6,11,17- -1,4- -3, (M2) (4pg/mL)
24 - 20 -
25 20 2g( 6mg) (4pg/mL) 0.06%
26 AUC (pghr/mL) AUC (pghr/mL) AUC (pghr/mL) Kel (hr -1 ) Kel (hr -1 ) Kel (hr -1 ) 7880(%)
27 CYP %
28 2-24 -
29 ODT 3, (0.43%) 4 (0.11%) 4 (0.11%) 4 (0.11%) 4 (0.11%) 2, (1.60%) 13 (0.61%) 7 (0.54%) 6 (0.28%) 5 (0.24%) 5 (0.24%) (1.65) 6 (0.82%) 5 (0.69%) 4 (0.55%) ( ) ODT
30 - 26 -
31 ODT (ODT)
32 - 28 -
33 17) 2) ( ) 80mg/kg 18)19) 1) (SD 5 n=20 20) 0.04mg/kg/day15 2) ( n=3 3) 0.2mg/kg/day13 2mg/kg/day 3) ( n=2 2) 0.1mg/kg/day 1 5mg/kg/day 50mg/kg/day 2 18) 1) (SD 5 n=30 30) mg/kg/day 52 (4 ) 0.04mg/kg/day 0.01mg/kg/day 2) ( n=6 6) mg/kg/day 0.01mg/kg/day 0.01mg/kg/day
34 SD 6 (n=20) 60 (n=20) mg/kg/day 0.08mg/kg/day 0.6mg/kg/day 0.6mg/kg/day 0.08mg/kg/day 0.08mg/kg/day 0.01mg/kg/day (SD 10 n=30) mg/kg/day 0.08mg/kg/day 10mg/kg/day 0.08mg/kg/day ( n=12) mg/kg/day 2mg/kg/day 0.4mg/kg/day 0.08mg/kg/day (SD 10 n=25) mg/kg/day 0.01mg/kg/day 0.08mg/kg/day 0.08mg/kg/day 0.6mg/kg/day 24) (Hartley n=5) ASA PCA 24) (Hartley ) 24) (Hartley ) Maximization
35 25) 3H AUC H AUC H- (0.1mg/kg) H- (0.4mg/kg)
36 (SD ) 3H- (0.6mg/kg) % 8.6% 11.2% 12% (SD ) 3H- (0.6mg/kg) % 10.5% 13.3% 14% 18 3H- 24 ( 0.4mg/kg)
37 g105g5010g10 500g 5g105g5010g10 10g1010g
38 AM 760 4AM AMZ M N Q
39 1) ( ) 2) ( ) 3) ( ) 4) ( ) 5) 0.3%Deprodone Propionate (DP ) 5(9)159,1989 6) DP ( ) 7) 67(10)1935,1985 8) Therapeutic Research5(6)955,1986 9) ( ) 10) DP DP ( ) 11) Deprodone Propionate(DP) ( ) 23(15)93, ) DP-L( ) ( ) 13) Deprodone propionate ( ) 14) ( ) 15) Deprodone propionate(dp) ( ) 16) ( ) 17) DP ( ) 18) ( ) 19) Deprodone Propionate(DP) (6)7, ) Deprodone Propionate(DP) 24(6)25, ) Deprodone Propionate(DP) 24(6)37, ) Deprodone Propionate(DP) 24(6)59, ) ( ) 24) Deprodone Propionate(DP) ( ) 23(15)7,
40 25) ( ) 26) ( ) 27) Deprodone Propionate ( ) 23(15)103, ) ( ) 29) ( ) 30) ( )
41 - 37 -
42 - 38 -
43 MKI10506G ECL DB003A
1 MR 63 2 IF 10 3 IF 2 IF IF IF 3 IF A4 9 IF IF IF 11 1 IF IF 4 IF IF MR IF IF MR Drug Safety Update IF
2003 7 3 872189 873919 IF 1998 9 PROBEAN CAP. 1 250mg Polyenephosphatidylcholine 1998 9 16 1999 7 9 1999 7 FAX IF 2003 7 1 MR 63 2 IF 10 3 IF 2 IF IF IF 3 IF A4 9 IF IF IF 11 1 IF IF 4 IF IF MR IF IF MR
More informationIF 1 MR 63 2 IF 10 3 IF 2IF IF IF 3IF A4 9 IF IF IF 11 1 IF IF 4IF IF MR IF IF MR Drug Safety Update IF
2008 2 3 87269 IF19989 100g 700g 30g SucrosePovidoneIodine 1999 3 15 1999 7 9 2000 5 IF 2008 2 IF 1 MR 63 2 IF 10 3 IF 2IF IF IF 3IF A4 9 IF IF IF 11 1 IF IF 4IF IF MR IF IF MR Drug Safety Update IF 1981
More informationIF MR 63 IF 10 IF IF IF IF A4 IF IF IF 11 IF IF IF IF MR IF IF MR Drug Safety Update() IF
200823 877122 IF19989 HYDROPHILIC OINTMENT 1g 250mg 200mg 120mg 60 40mg 10mg 1mg 1mg HydrophilicOintment 200821 19518 19977 IF20082 IF MR 63 IF 10 IF IF IF IF A4 IF IF IF 11 IF IF IF IF MR IF IF MR Drug
More information1999年3月作成(新様式第1版)
200622 19989 871313 1mL4mg JAN oxybuprocaine hydrochloridejan 2002621 20037 4 19667 1 FAX 2005 10 29607 05 1 63 () 103 2 3 49 111 4 Drug Safety Update 1. -------------------------------------1 2. -----------------------1
More informationグリセオール注インタビューフォーム
2006 8 3 873999 871319 IF 1998 9 FAX 1 200mL 300mL 500mL 20g 30g 50g 10g 15g 25g 1.8g 2.7g 4.5g 0.9W/V 200mL500mL 1979 3 13 2004 7 9 1979 5 15 2006 8 300mL 1979 3 13 2004 7 9 1982 11 1 IF 1 MR 63 IF 10
More informationuntitled
~ ~ ~ ~ ~ 22 14 10 50cm 2124 15 21 29.5 11, 12 12 20 4040 10 60 60 10 20 20 11 ç ç çç 6070 ç ç çç p. ç çç 4.5cm2.5cm 25 http://www.crdc.gifu-u.ac.jp/edsoftol/water/
More informationエコリシン点眼液/眼軟膏インタビューフォーム
2011 11 4 871319 1mL 5mg 5mg15 1g 5mg 5mg15 JAN JAN Erythromycin LactobionateJAN Colistin Sodium MethanesulfonateJAN 1970 3 31 1970 8 1 1970 7 20 TEL0120-921-839 06-6321-7056 9 17 https://www.santen.co.jp/medical/admin/a300.jsp
More information:,, : - 7 -
31 ~ ~ - 6 - :,, : - 7 - (),,,,,,; ~ ~ *1 *2 6,,,~,,~ - 8-32 ,, ( );( ),,,,,, ~ ~ ~,,,, (),,,,, - 9 - 33 ~*~ ~~ ~, ~ ~ ~ ~ ~, ~~,,,, - 10 - BCG () g ) BCG BCG,, 34 ,,,, (),,,,,,,,,,,,,, () ( 3 90 [7 6
More informationエディロールカプセルインタビューフォーム
2012 4 5 873112 2008 () 1 0.5g 0.5g 0.75g 0.75g JAN EldecalcitolJAN 2011 1 21 2011 3 11 2011 4 11 TEL0120-591-818 03-3985-5599 8:3017:00 http://www.taishotoyama.co.jp/ 20124 http://www.info.pmda.go.jp/
More informationRF_1
RF_1 10/04/16 10:32 http://rftechno.web.infoseek.co.jp/rf_1.html 1/12 RF_1 10/04/16 10:32 http://rftechno.web.infoseek.co.jp/rf_1.html 2/12 RF_1 10/04/16 10:32 http://rftechno.web.infoseek.co.jp/rf_1.html
More information12331514 20131126 1 2 3 1 2 2 52495 4 1122 1 2 2 2 3 45 1 2 1 3 2 4 Z 8305 1962 8 4 2 1 2 2 35 3 12 1 2 32 4418 4 1 5 323 6 11111 332 5 342 6 1 23 4 2 3 7 3 2 3 25175 19132 8 2 1 1 2 3 4 5 6 7 2 1 2 3
More informationMicrosoft Word - 表紙資料2-4
(1) / 130 g 25 g 520% 170 g 30 g 560% 70 mg 600 mg 11.6% 0 10.5 mg 0% (1) (2) / 50100 g 25 g 200400% 50100 g 30 g 167333% 5001000 mg 600 mg 83167% 1020 mg 10.5 mg 95190% (2) / (1) 45.6 g 30 g 152% (2)
More informationCTD 2 2.6 5.3mg 0.4mg 0.6mg 0.8mg 1.0mg 1.2mg 1.4mg 1.6mg 1.8mg 2.0mg 12mg 2.6 Page 3 2.6.6...5 2.6.6.1...6 2.6.6.2...9 2.6.6.3...9 2.6.6.4... 11 2.6.6.5... 11 2.6.6.6... 11 2.6.6.7... 11 2.6.6.8... 11
More informationuntitled
-- -- -3- % % % 6% % % 9 66 95 96 35 9 6 6 9 9 5 77 6 6 5 3 9 5 9 9 55 6 5 9 5 59 () 3 5 6 7 5 7 5 5 6 6 7 77 69 39 3 6 3 7 % % % 6% % % (: ) 6 65 79 7 3 36 33 9 9 5 6 7 3 5 3 -- 3 5 6 76 7 77 3 9 6 5
More informationuntitled
NO. 2007 10 10 34 10 10 0570-058-669 http://www.i-nouryoku.com/index.html (40 ) () 1 NO. 2007 10 10 2.2 2.2 130 70 20 80 30 () () 9 10 () 78 8 9 () 2 NO. 2007 10 10 4 7 3 NO. 2007 10 10 40 20 50 2 4 NO.
More information1 z q w e r t y x c q w 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 R R 32 33 34 35 36 MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR MR
More information199004_渓仁会_年次報告書
() () () () () () () () () () () () () () () (4) (5) (6) 4 (7) 5 (8) 6 (9) 7 () 8 () 7 4 5 () 6 () 6 7 9 () 4 () 4 () 4 () 4 () 4 () 4 () 4 () 4 () 44 45 () 4 46 () 48 () 48 () 49 () 49 5 () 5 () 5 ()
More information, 360ml P , 360ml P , 360ml P , 40, 720ml P , 14, 2
3-1 3-1 20 2600, 20, 360ml P.35 3-2 3-2 16 2700, 16, 280ml P.35 3-3 3-3 20 2600, 20, 360ml P.35 3-4 3-4 19 2600, 19, 340ml P.35 3-5 3-5 20 2900, 20, 360ml P.35 3-6 3-6 18 3000, 18, 320ml P.35 3-7 3-7 18
More informationuntitled
2001 4 26 2003 5 22 2004 7 12 2004 7 15 54 2004 7 21 14 2004 9 16 62 IUPAC4--2--N,N --5-p --1-2 17.07 mg/kg / 100 0.17 mg/kg /ADI cyazofamidiso IUPAC 4--2--N,N- -5-p --1-4-chloro-2-cyano-N,N -dimethyl-5-p
More informationL- 19 L L- L-
0131001 15 1 31 49 35 145 14 5 19 4 23 15 3 10 7 15 634 1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 L- 19 L- 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49
More information日本標準商品分類番号
2009 10 ( 5 ) 872646 IF 1998 9 1g 0.5mg(0.05%) 0.5mg(0.05%) ifluprednate 0.05 0.05 1994 3 15 2009 9 2000 8 20 FAX IF 2009 7 1 FLUNERT Ointment FLUNERT Cream Difluprednate C27H34F2O7 508.55 6,9-Difluoro-11,17,21-trihydroxy-1,4-
More information% %
4 8 4 5 414.5 172.1 41.5% 39.8 10% 17 186.4 70.8 4 9 10 11 3 1-1 - 2-2 - - 3 - 10% - 4 - 4060% 5560% 60% 40% 3040 1520 1015 411 7 4 11 610 7080 5060 100 3040 13-5 - 1015 4045 3.04.0 5.06.0 1.52.0 1.01.5
More informationCAS H 3 C C CH 2 C 9 H tert d = hpa
1 200140 35 CAS 98839 1335-2- H 3 C C CH 2 C 9 H 10 118.18 1 99 4-tert- 1. 2-23.2 2 163164 2 54 574 3 0.96.6 20 d 4 0.9082 2 4.07 = 1 2.5 hpa 1.9 mmhg20 2 4 log Pow3.48 3.44 m/z 118, 1.0 103 0.58 91 0.21
More informationuntitled
6 ( ). 1.. 1. 2. 3. 4. 5. ( ) 6. 7. 8. . 1. 1) 1 (12 3 ) 2 2) 3) ( ) ( ) 4) 2 () 2 2 3 5) ( ) R-Book ATLAS () 8 12 7 18 14 16 10 21 14 23 16 18 16 18 12 25 4 14 21 1 4 2 3 4 4 1 2 7 5 1 2 5 7 9 1 1 5 5
More informationスライド タイトルなし
2395 20 3 2008 5 16 SHIN NIPPON BIOMEDICAL LABORATORIES,LTD. 1 2 CONTENTS. 20 3 CFO. 2008 CEO... Translational Translational 3 . 20 3 CFO 4 20 3 P/L 19 3 20 3 17,289 19,500 19,647 +2,358 +147 1,125 1,453
More information参考資料5 農薬評価書 メタアルデヒド(食品安全委員会資料)
1 3 3 4 5. 6 1. 6 2. 6 3. 6 4. 6 5. 6 6. 6 7. 6. 7 1. 7 2. 8 (1) 8 (2) 9 (3) 9 (4) 10 (5) 10 3. 11 (1) 11 (2) 11 (3) 11 (4) 12 4. 12 (1) 12 (2) 12 (3) 13 5. 13 6. 13 7. 14 8. 15 9. 16 10. 16 (1) 90 16-1
More information平成20年5月 協会創立50年の歩み 海の安全と環境保全を目指して 友國八郎 海上保安庁 長官 岩崎貞二 日本船主協会 会長 前川弘幸 JF全国漁業協同組合連合会 代表理事会長 服部郁弘 日本船長協会 会長 森本靖之 日本船舶機関士協会 会長 大内博文 航海訓練所 練習船船長 竹本孝弘 第二管区海上保安本部長 梅田宜弘
More information
untitled
2007 12 1 871146 IF 1998 9 350mg 250mg 100mg 10mg 10mg Sodium Salicylate Sulpyrine Hydrate Caffeine Hydrate Allobarbital Procaine Hydrochloride 2007 8 31 2007 12 21 1955 2 FAX TEL FAX IF 2007 12 6 IF 1
More information表紙/151708H
! " # $ % & ' ( ) ! #! $! " % & " ' " # * + $ %, &! & ', '! " # $ (! " # $ )! " # $ !!$ "! " # $ #! " # $ $! " # $ %! " # $ ! " # " 1 $ 2 " $ % 3 & % ' ( 4 ( ) * ' + 5, -. 6 / 0 0 +, 1 -. 2 3 /! /!%!!
More informationDPCはやわかり表紙_2014_H1-H4.indd
C O N T E N T S 1 2 3 4 5 6 7 A B AB 15 15 25 2SD 1 1 A B 15 AB 25 2SD 1 1 1 A B 25 2SD 10 10 10 AB 1 1 1 1 A 1 A 1 B1 15 B 2SD 8 9 10 11 12 13 14 15 16 17 18 DPCA DPCA 7 DPCA DPCA 7 DPCA DPCA 7 DPCA DPCA
More information20mg CTD 2.4 2.4 2.4... 5 2.4.1... 5 2.4.2... 7 2.4.3... 10 2.4.4... 13 2.4.5... 18 2.4.6... 20 3 2.4 2.4 2.4.1 JNS002 ( HSPC) N-(Carbonyl-methoxypolyethylene glycol 2000)-1,2- distearoyl-sn-glycero-3-phosphoethanolamine
More information(1) (2) (1) (2) (1) Seg (2) Seg (3) Seg (4) Seg (1) (2) (3) ( ) (1) (PCA)...12
(1)...109 (2)...110 (1) 28...111 (2) 28...113 (1) Seg...115 (2) Seg...117 (3) Seg...119 (4) Seg...120 (1)...122 (2)...122 (3) ( )...126 (1) (PCA)...127 (2) Draize...128 (1) Ames...129 2 in vitro...132
More information裁定審議会における裁定の概要 (平成23年度)
23 23 23 4 24 3 10 11 12 13 14 () 1 23 7 21 23 12 14 (19 ) 30 1.876% 60 8 24 19 78 27 1 (10) 37 (3) 2 22 9 21 23 5 9 21 12 1 22 2 27 89 10 11 6 A B 3 21 12 1 12 10 10 12 5 1 9 1 2 61 ( 21 10 1 11 30 )
More information和県監査H15港湾.PDF
...1...1...1...1...1...1...1...1...2...2...2...3...3...3...5...5...10...11...12...13...13...13...14...14...14...14...14...14...15...15...15...15...15 ...16...17 14...17...18...18...19...21...23 2...25...27...27...28...28...28
More informationuntitled
() () () () () ( ) () ( ) () ( ) () 2 () () 2 () () ( ) () () () 2 () () 2 3 ( ) () ( ) 2 3 4 () () 2 3 4 () () ( )( ) ( ) 2 ( ) 3 () () 2 3 () () 2 3 () () () () () () () () (( ) ( ) (( ))( )( ) ) 2 3
More information180 30 30 180 180 181 (3)(4) (3)(4)(2) 60 180 (1) (2) 20 (3)
12 12 72 (1) (2) (3) 12 (1) (2) (3) (1) (2) (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (1) (2) 180 30 30 180 180 181 (3)(4) (3)(4)(2) 60 180 (1) (2) 20 (3) 30 16 (1) 31 (2) 31 (3) (1) (2) (3) (4) 30
More informationuntitled
1....1 2....2 2.1...2 2.2...2 3....14 3.1...14 3.2...14 4....15 4.1...15 4.2...18 4.3...21 4.4...23 4.5...26 5....27 5.1...27 5.2...35 5.3...54 5.4...64 5.5...75 6....79 6.1...79 6.2...85 6.3...94 6.4...
More information113 120cm 1120cm 3 10cm 900 500+240 10 1 2 3 5 4 5 3 8 6 3 8 6 7 6 8 4 4 4 4 23 23 5 5 7
More informationuntitled
21 14 487 2,322 2 7 48 4 15 ( 27) 14 3(1867) 3 () 1 2 3 ( 901923 ) 5 (1536) 3 4 5 6 7 8 ( ) () () 9 10 21 11 12 13 14 16 17 18 20 1 19 20 21 22 23 21 22 24 25 26 27 28 22 5 29 30cm 7.5m 1865 3 1820 5
More information1948 1907 4024 1925 14 19281929 30 111931 4 3 15 4 16 3 15 4 161933 813 1935 12 17 11 17 1938 1945 2010 14 221 1945 10 1946 11 1947 1048 1947 1949 24
15 4 16 1988 63 28 19314 29 3 15 4 16 19283 15294 16 1930 113132 3 15 4 16 33 13 35 12 3 15 4 16 1945 10 10 10 10 40 1948 1907 4024 1925 14 19281929 30 111931 4 3 15 4 16 3 15 4 161933 813 1935 12 17 11
More information<91E6825289F1938C966B95FA8ECB90FC88E397C38B5A8F708A778F7091E589EF8EC08D7388CF88F5837D836A83858341838B566572312E696E6464>
More information
Microsoft Word - 入居のしおり.doc
1 1 2 2 2 3 2 4 3 5 3 6 3 7 3 8 4 1 7 2 7 3 7 4 8 5 9 6 9 7 10 8 10 9 11 10 11 11 11 12 12 13 13 1 14 2 17 3 18 4 19 5 20 6 22 (1) 24 (2) 24 (3) 24 (4) 24 (5) 24 (6) 25 (7) 25 (8) 25 (9) 25 1 29 (1) 29
More information( )
( ) () () 3 cm cm cm cm cm cm 1000 1500 50 500 1000 1000 1500 1000 10 50 300 1000 2000 1000 1500 50 10 1000 2000 300 50 1000 2000 1000 1500 50 10 1000 2000 300 30 10 300 1000 2000 1000 1500 1000
More information2002 (1) (2) (3) (4) (5) (1) (2) (3) (4) (5) (1) (2) (3) (4) (5) (6) (7) (8) (1) (2) (3) (4) (1) (2) (3) (4) (5) (6) (7) (8) No 2,500 3 200 200 200 200 200 50 200 No, 3 1 2 00 No 2,500 200 7 2,000 7
More information-26-
-25- -26- -27- -28- -29- -30- -31- -32- -33- -34- -35- -36- -37- -38- cm -39- -40- 1 2 3 4 4 3 2 1 5 5-41- -42- -43- -44- -45- -46- -47- -48- -49- -50- cm -51- -52- -53- -54- -55- -56- -57- -58- -59- -60-
More information-1- 4 1 2 4-2- -- 2 2 cm 0 80cm 2 80cm 80cm 80cm 50cm 80cm 50cm 6 80cm 100 50 50 cm 10 6 4 50cm 4 4 50cm -4- -5- cm 50cm 4 4 4 50cm 50cm 4 80cm 50cm 80cm 50cm 6 cm -6- 20 250cm 1 2 1 4 0cm 60cm cm cm 1
More information河川砂防技術基準・基本計画編.PDF
4 1 1 1 1 1 2 1 2.1 1 2.2 2 2.3 2 2.4 2 3 2 4 3 2 4 1 4 1.1 4 1.2 4 2 4 2.1 4 2.2 4 2.3 5 2.4 5 2.5 5 2.5.1 5 2.5.2 5 2.6 5 2.6.1 5 2.6.2 5 2.6.3 5 2.6.4 5 2.6.5 6 2.7 6 2.7.1 6 2.7.2 6 2.7.3 6 2.7.4
More information4 100g
100g 10 20 30 40 50 60 70 80 4 5 7 9 12 15 19 24 60 100 10 80 100 20 10 5 20 195 20-1- 60 60 15 100 60 100 15 15 15 100 15 15 60 100 10 60 100 100 15 10 10 60 100 15 10 15 10 5-2- 80 80 24 100 80 100 24
More information中高齢者の健康・いきいきライフスタイルづくり調査
1 -- -- 10 11 12 1998-2000 Exercise: A Guide from the National Institute on Aging 1 61-80 26 T PHA Streptoccocal enterotoxin ASEA (IL-2; Th1 ) IL-4Th2 IgE T T - Bcl-2 Fas T PHA SEA IL2 T PHA SEA IL2
More information年次報告書-2003年(平成15年)度版-
9876 ,g,g,g,9g 8 6 6 6 6 8 7 8 6 7 8 7 9 7 6 6 6 7 7 8 6 8 7 6 6 8 7 8 7 7 9 7 6 98 76,8 () ( ) 8,68.7 7,76, 9,87.9 8,67, () g g g g g g g g g g g g g g g g g g g g g g g g g g g g () () 9 8 88 6 8 88
More information200mg 2005 3 876179 2002 3 3 200mg VFEND for Intravenous Use (1) (2) [4.1 ] (3) [4.2 ] (1) [1] (2) (3) [1] 3
More information55 a h dd s q q w w w d d d d d d d d d
54 q w e r q w e 55 a h dd s q q w w w d d d d d d d d d w e r d q 56 57 ggg gg w e g g g g g g g g g g g g g g g g 58 r o o 59 o o o o o o o o 60 o o o o o o o 61 t f q w e o 62 g q 63 w e 64 r 65 t qw
More informationIF MR 63 2 IF 10 3 IF IF IF A4 9 IF IF IF 11 1 IF IF IF MR IF IF MR Drug Safety Update IF
2009 2 1 872612 IF 1998 9 IODINE M DISINFECTANT SOLUTION 10 10w/v 100mL 10g( 1g) PovidoneIodine 2008 10 15 2008 12 19 2009 1 6 IF 2008 12 IF MR 63 2 IF 10 3 IF IF IF A4 9 IF IF IF 11 1 IF IF IF MR IF IF
More information取扱説明書
TE-300 C n n 14-0% n n n n n n n n n n n n OP PGM m l o J R t m v Å x u 1 9 0 ^. K E [ P p !,!' L - % s c w D n n n n n n n n n m n n m n n n l l 1 1200!!200 2 3 g 2000 g!200 800 m K l 1 300! 800 "
More informationuntitled
- 1 - - 2 - OFF - 3 - 18-4 - - 5 - - 6 - (1) (2) No 1 0099240130 CL-10 2 0099240040 CL-3-7 - - 8 - 50Hz 250 / - 9 - 6. 1 6. 2 R 6. 3 V 6. 4 R - 10 - 6. 5 6. 6 6. 7-11 - 6. 8 500mm 6. 9 4. 6. 10-12 - 6.
More information